Abstract:Background tPA (tissue‐type plasminogen activator) remains the only approved drug for acute ischemic stroke, with a potentially serious adverse effect: hemorrhagic transformation. The effects of antithrombotic agents on tPA‐induced hemorrhagic transformation after ischemic stroke are not clearly defined. We performed a systematic review and meta‐analysis in preclinical studies aiming to evaluate the efficacy of antithrombotic agents on tPA‐induced hemorrhagic transformation after ischemic stroke. Methods and Results We conducted a systematic review and meta‐analysis of studies testing antithrombotic agents in animal models of tPA‐induced hemorrhagic transformation. The pooled effects were calculated using random‐effects models, and heterogeneity was explored through meta‐regression and subgroup analyses. Publication bias was assessed using trim and fill method and the Egger test. The efficacy of 18 distinct interventions was described in 22 publications. The pooled data showed a significant improvement in cerebral hemorrhage, infarct size, and neurobehavioral outcome in treated compared with control animals (standardized mean difference, 0.45 [95% CI, 0.11–0.78]; standardized mean difference, 1.18 [95% CI, 0.73–1.64]; and standardized mean difference, 0.91 [95% CI, 0.49–1.32], respectively). Subgroup analysis indicated that quality score, random allocation, control of temperature, anesthetic used, stroke model used, route of drug delivery, time of drug administration, and time of assessment were significant factors that influenced the effects of interventions. Conclusions Administration with antiplatelet agents revealed statistically significant improvement in all the outcomes. Anticoagulant agents showed significant effects in infarct size and neurobehavioral score, but fibrinolytic agents did not show any significant improvement in all the outcomes. The conclusions should be interpreted cautiously given the heterogeneity and publication bias identified in this analysis. Nonstandard Abbreviations and Acronyms HT hemorrhagic transformation RESTART Restart or Stop Antithrombotics Randomized Trial RETRACE German‐Wide Multicenter Analysis of Oral Anticoagulation Associated Intracerebral Hemorrhage SMD standardized mean difference Clinical Perspective What Is New? Antithrombotic therapy resulted in significant improvement of cerebral hemorrhage, infarct size, and neurobehavioral score in animal models of tPA (tissue‐type plasminogen activator)–induced hemorrhagic transformation. Study quality score, random allocation, control of temperature, anesthetic used, stroke model, route of drug delivery, time of drug administration, and time of assessment were significant factors that influenced the effects of antithrombotic agents. What Are the Clinical Implications? Our results revealed that antiplatelet agents and anticoagulant agents were the more effective subtypes of antithrombotic agents, whereas fibrinolytic agents produced no significant differences. Results of this analysis provided guidance for future animal studies investigating the efficacy of antithrombotic agents on tPA‐induced hemorrhagic transformation and valuable insight into clinical drug use and trial design. Early intravenous thrombolysis with tPA (tissue‐type plasminogen activator) remains the only US Food and Drug Administration approved agent for acute ischemic stroke treatment. However, tPA can lead to an increased risk of hemorrhagic transformation (HT), especially beyond 4.5 hours of stroke onset. 1 HT is often associated with significant mortality and disability rate. 2 Therefore, it is important to control the risk of HT when tPA is used in patients after acute ischemic stroke. Antithrombotic agents are widely used to prevent and treat thrombosis in the venous and arterial circulations. 3 After acute ischemic stroke, antithrombotic therapy is recommended to prevent recurrent thromboembolism.<a class="tab-link" hre -Abstract Truncated-

Angioedema and Hemorrhage After 4.5-Hour tPA (Tissue-Type Plasminogen Activator) Thrombolysis Ameliorated by T541 via Restoring Brain Microvascular Integrity

Tissue plasminogen activator expression and barrier properties of human brain microvascular endothelial cells.

Angong Niuhuang Wan reduces hemorrhagic transformation and mortality in ischemic stroke rats with delayed thrombolysis: involvement of peroxynitrite-mediated MMP-9 activation

tPA Mobilizes Immune Cells that Exacerbate Hemorrhagic Transformation in Stroke

YangXueQingNaoWan attenuated blood brain barrier disruption after thrombolysis with tissue plasminogen activator in ischemia stroke

QiShenYiQi Inhibits Tissue Plasminogen Activator–Induced Brain Edema and Hemorrhage after Ischemic Stroke in Mice

Prothymosin alpha and its mimetic hexapeptide improve delayed tissue plasminogen activator‐induced brain damage following cerebral ischemia

tPA Helpers in the Treatment of Acute Ischemic Stroke: Are They Ready for Clinical Use?

Cell permeable HMGB1-binding heptamer peptide ameliorates neurovascular complications associated with thrombolytic therapy in rats with transient ischemic stroke

YiQiFuMai Lyophilized Injection ameliorates tPA-induced hemorrhagic transformation by inhibiting cytoskeletal rearrangement associated with ROCK1 and NF-κB signaling pathways

Low-dose tissue plasminogen activator is as effective as standard tissue plasminogen activator administration for the treatment of acute ischemic stroke.

J147 Reduces tPA-Induced Brain Hemorrhage in Acute Experimental Stroke in Rats

Early Administration of Pyrrolidine Dithiocarbamate Extends the Therapeutic Time Window of Tissue Plasminogen Activator in a Male Rat Model of Embolic Stroke

Adjunctive Therapy Approaches for Ischemic Stroke: Innovations to Expand Time Window of Treatment

Cold Case of Thrombolysis: Cold Recombinant Tissue Plasminogen Activator Confers Enhanced Neuroprotection in Experimental Stroke

Encapsulation of tissue plasminogen activator in pH-sensitive self-assembled antioxidant nanoparticles for ischemic stroke treatment - Synergistic effect of thrombolysis and antioxidant

Early Ischemic Blood Brain Barrier Damage: A Potential Indicator for Hemorrhagic Transformation Following Tissue Plasminogen Activator (tpa) Thrombolysis?

tPA supplementation preserves neurovascular and cognitive function in Tg2576 mice

Antithrombotic Agents for tPA-Induced Cerebral Hemorrhage: A Systematic Review and Meta-Analysis of Preclinical Studies.

Abstract 40: Xenon-Loaded Liposomes in Combination with IV Tpa Extends the Time Window for Treatment of Thrombotic Stroke

Phthalide derivative CD21 attenuates tissue plasminogen activator-induced hemorrhagic transformation in ischemic stroke by enhancing macrophage scavenger receptor 1-mediated DAMP (peroxiredoxin 1) clearance